New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - carboplatin 10 mg/ml;  ;   - solution for injection - 10 mg/ml - active: carboplatin 10 mg/ml     excipient: nitrogen water for injection

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dantrolene sodium hemiheptahydrate 20mg - powder for injection - 20 mg - active: dantrolene sodium hemiheptahydrate 20mg excipient: mannitol - latest regulatory activity

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ethinylestradiol 20ug; levonorgestrel 100ug; ethinylestradiol 0.02mg; levonorgestrel 0.1mg - film coated tablet - active: ethinylestradiol 20ug levonorgestrel 100ug excipient: glycol montanate lactose monohydrate macrogols magnesium stearate microcrystalline cellulose opadry pink ys-1-14587-a polacrilin potassium glycol montanate lactose monohydrate macrogol 1500 magnesium stearate microcrystalline cellulose opadry white y-5-18024-a polacrilin potassium aquapolish p white 010.66 magnesium stearate starlac active: ethinylestradiol 0.02mg levonorgestrel 0.1mg excipient: wax e pharma lactose magnesium stearate microcrystalline cellulose opadry pink ys-1-14587-a polacrilin potassium polyethylene glycol 1450 purified water wax e pharma lactose macrogol 1500 magnesium stearate microcrystalline cellulose opadry white y-5r-18024-a polacrilin potassium purified water - loette is indicated for the prevention of pregnancy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - acipimox 250mg - capsule - 250 mg - active: acipimox 250mg excipient: colloidal hydrated silica gelatin iron oxide red iron oxide yellow magnesium stearate sodium laurilsulfate starch titanium dioxide - olbetam is indicated for the treatment of lipid disorders characterised by elevated plasma levels of triglycerides (fredrickson type iv hyperlipoproteinaemia), or both triglycerides and cholesterol (type iib hyperlipoproteinaemia). olbetam should be prescribed only for patients with lipid or lipoprotein abnormalities demonstrated by laboratory tests and where diet alone is insufficient to correct the condition.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - doxorubicin hydrochloride 2 mg/ml - solution for injection - 2 mg/ml - active: doxorubicin hydrochloride 2 mg/ml excipient: hydrochloric acid as 0.5m, to ph 3 sodium chloride water for injection - doxorubicin has produced significant therapeutic responses in a number of solid tumours and haematologic malignancies, and is commonly used in the treatment of the following tumours: · carcinoma of the breast · carcinoma of the lung · carcinoma of the ovary · transitional bladder cell cancer · neuroblastoma · wilms' tumour · soft tissue sarcomas · osteosarcoma · acute lymphocytic - lymphoblastic leukaemia · acute myelogenous leukaemia · non-hodgkin's lymphoma · hodgkin's disease doxorubicin has also shown antitumour activity in the following adult and paediatric malignancies: · carcinoma of the thyroid · carcinoma of the endometrium · carcinoma of the head and neck · carcinoma of the stomach · primary hepatocellular carcinoma · non-seminomatous carcinoma of the testis · carcinoma of the prostate · ewing's sarcoma · rhabdomyosarcoma · multiple myeloma · chronic leukaemias

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - benzathine benzylpenicillin tetrahydrate 442 mg/ml (1,200,000u/2.3ml) - suspension for injection - 1,200,000 u/2.3 ml - active: benzathine benzylpenicillin tetrahydrate 442 mg/ml (1,200,000u/2.3ml) excipient: carmellose sodium lecithin methyl hydroxybenzoate povidone propyl hydroxybenzoate sodium citrate dihydrate water for injection - intramuscular benzathine benzylpenicillin is indicated in the treatment of infections due to penicillin-sensitive micro-organisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. the following infections will usually respond to adequate dosage of intramuscular benzathine benzylpenicillin: · streptococcal infections (group a - without bacteraemia). mild-to-moderate infections of the upper respiratory tract (eg., pharyngitis). · venereal infections - syphilis, yaws, bejel and pinta.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - varenicline tartrate 1.71mg equivalent to 1 mg varenicline;  ;   - film coated tablet - 1 mg - active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - minoxidil 10mg - tablet - 10 mg - active: minoxidil 10mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated as adjunctive therapy in adults with severe refractory hypertension which has failed to respond to extensive multiple therapy. when used in combination with an accompanying diuretic and beta-blocker, minoxidil has been shown to reverse encephalopathy and retinopathy in severe hypertensives.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - riltozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose;  ;  ;  ;  ; tozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose;  ;  ;  ;   - suspension for injection - 0.1 mg/ml - active: riltozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose         tozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose         excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol sucrose trometamol trometamol hydrochloride water for injection - comirnaty has provisional consent for the indication below: active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. the use of this vaccine should be in accordance with official recommendations.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - famtozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose;  ;  ;  ;  ; tozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose;  ;  ;  ;   - suspension for injection - 0.1 mg/ml - active: famtozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose         tozinameran 0.05 mg/ml equivalent to 15µg/0.3ml dose         excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol sucrose trometamol trometamol hydrochloride water for injection - comirnaty original/omicron ba.4/ba.5 has provisional consent for the indication below: a booster dose for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. the use of this vaccine should be in accordance with official recommendations.